Clinical trials: Hepatic Malignancies
Liver Cancer, Liver Failure
Quantitative MRI and Outcomes of Liver Resection
The present observational study aims to assess the benefit of this quantitative multiparametric magnetic resonance imaging (MRI) in clinical practice, to quantify future liver remnant performance, and to accurately predict the…
- Conditions
- Liver Cancer, Liver Failure, Bile Leak, Liver Metastases
- Trial name
- NCT06181318
- Testing
- Multiparametric MRI scan of the liver
- Volunteers
- 33 people
- Sponsor
- University Hospital Heidelberg
Arteriovenous Malformation, Hemangioma
Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB
This is an open-label whole-body PET/CT study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 68Ga-NEB in healthy volunteers and patients with suspected…
- Conditions
- Arteriovenous Malformation, Hemangioma, Neoplasms Lymph Nodes, Lymphedema
- Trial name
- NCT02496013
- Testing
- 68Ga-NEB
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Colorectal Cancer, Hepatic Metastasis
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response…
- Trial name
- AVAMET (NCT01493713)
- Testing
- Evaluate the correlation of overall different objective response.
- Where
- 21 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer With Liver Metastases
ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM)
Currently, the tumor response of operated colorectal liver metastases is assessed by histology of the resection specimen.The histological data make it possible to define categories (responder, partial responder, non-responder).
- Trial name
- MetaIRM (NCT06552117)
- Testing
- an elastoMRI sequence
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002716
- Testing
- dexamethasone, floxuridine, fluorouracil
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 135 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatic Cell Carcinoma
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to…
- Trial name
- NCT06515314
- Testing
- AFP Specific T Cell Receptor T Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Ruiliyuan Biotechnology Co., Ltd.
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma.
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer
- Trial name
- ELUCIDATE (NCT06342414)
- Testing
- ELUCIDATE
- Where
- 5 sites in United States, Japan
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Response of Hepatic Tumors to Radioembolization
The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis.
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastasis
- Trial name
- RESRAD (NCT01775280)
- Testing
- Injection of Ytttrium-90 microspheres into the hepatic artery
- Where
- Switzerland
- Sponsor
- University of Zurich
Pancreatic Neoplasms, Cholangiocarcinoma
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
Therasphere is a form of treatment that has been designed to selectively deliver radiation to the cancer within the patient's liver.
- Trial name
- NCT01434459
- Testing
- Gemcitabine with TheraSphere
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Liver Metastases
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
This is an open label fixed dose phase Ib of anti-CEA CAR-T cells hepatic artery infusions and yttrium-90 SIR-Spheres in patients with CEA-expressing liver metastases.
- Trial name
- HITM-SIR (NCT02416466)
- Testing
- anti-CEA CAR-T cells, Sir-Spheres
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roger Williams Medical Center
Hepatic Small Vessel Neoplasm
Hepatic Small Vessel Neoplasm
Small-vessel hepatic tumor is a new tumor entity of vascular origin, described in 2016 by Gill et al, in a series of 17 patients.
- Trial name
- IMAHEP (NCT06067035)
- Testing
- Imaging
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin\&5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC). The program of FOLFOX-HAIC in HCC was performed for 1 day (HAIC 1d) or 2 days (HAIC 2d).
- Trial name
- NCT05476432
- Testing
- HAIC, FOLFOX 2d, FOLFOX 1d
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after…
- Trial name
- NCT06089382
- Testing
- Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Tongji Hospital
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Heart Failure, Copd
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus
- Trial name
- NCT04351880
- Testing
- Medically Tailored Meals
- Where
- 2 sites in United States
- Volunteers
- 650 people
- Sponsor
- Kaiser Permanente
Hepatic Malignant Neoplasm Primary Non-Resectable
Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy
Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP with the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
- Trial name
- NCT03266042
- Where
- 2 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Delcath Systems Inc.
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Trial name
- NCT01938729
- Testing
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.